{"name": "regdanvimab", "category": "drug", "content": "Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. Regdanvimab was approved for medical use in the European Union in November 2021.   == Medical uses == In the European Union, regdanvimab is indicated for the treatment of adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.   == Society and culture ==   === Legal status === In March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of data on regdanvimab. In October 2021, the EMA started evaluating an application for marketing authorization for the monoclonal antibody regdanvimab (Regkirona) to treat adults with COVID-19 who do not require supplemental oxygen therapy and who are at increased risk of progressing to severe COVID-19. The applicant is Celltrion Healthcare Hungary Kft. The European Medicines Agency (EMA) concluded that regdanvimab can be used for the treatment of confirmed COVID-19 in adults who do not require supplemental oxygen therapy and who are at high risk of progressing to severe COVID-19. In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for regdanvimab (Regkirona) for the treatment of COVID-19. The company that applied for authorization of Regkirona is Celltrion Healthcare Hungary Kft. Regdanvimab was approved for medical use in the European Union in November 2021.   === Names === Regdanvimab is the international nonproprietary name (INN).   == References ==   == Further reading == Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, et al. (January 2021). \"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein\". Nature Communications. 12 (1): 288. doi:10.1038/s41467-020-20602-5. PMC 7803729. PMID 33436577. Syed YY (December 2021). \"Regdanvimab: First Approval\". Drugs. 81 (18): 2133\u20137. doi:10.1007/s40265-021-01626-7. PMC 8558754. PMID 34724174.   == External links == \"Regdanvimab\". Drug Information Portal. U.S. National Library of Medicine."}